Compare RXT & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | ACIU |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 213.3M |
| IPO Year | 2020 | 2016 |
| Metric | RXT | ACIU |
|---|---|---|
| Price | $0.98 | $3.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.61 | ★ $10.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 02-19-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,688,500,000.00 | $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.63 | $644.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $1.43 |
| 52 Week High | $3.03 | $4.00 |
| Indicator | RXT | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 54.48 |
| Support Level | $0.96 | $3.02 |
| Resistance Level | $1.01 | $3.30 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 5.42 | 35.48 |
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.